Healthcare / Medical DevicesShanghai
$50.73
-0.78 (-1.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-251.4M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.1B
P/E
97.6x
↑EV/EBITDA
47.6x
↑ROE
3.8%
↑Gross Margin
66.6%
↑Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
—
FCF margin
-12.7%
FCF / Net income
-1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $767.7M · net income $78.2M · FCF $-97.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $767.7M | $767.7M | $743.5M | $744.8M | $488.5M |
| Net Income | $78.2M | $78.2M | $102.9M | $227.1M | $125.5M |
| EBITDA | $135.8M | $135.8M | $150.6M | $264.8M | $149.2M |
| EPS | 0.51 | 0.51 | 0.66 | 1.44 | 0.79 |
| Gross Margin | 66.6% | 66.6% | 67.4% | 68.6% | 66.3% |
| Operating Margin | 8.6% | 8.6% | 13.0% | 29.6% | 20.7% |
| Net Margin | 10.2% | 10.2% | 13.8% | 30.5% | 25.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.18 | 0.02 | 0.01 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-97.4M | $-97.4M | $-260.3M | $-251.4M | $-16.4M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 5.0% | 10.9% | 6.5% |
| Valuation | |||||
| P/E | 97.56 | 97.56 | 42.59 | 34.97 | 42.28 |
| EV/EBITDA | 47.57 | 47.57 | 25.35 | 27.21 | 30.79 |
| P/B | 3.19 | 3.19 | 2.06 | 3.75 | 2.75 |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | -0.2% | 52.5% | — |
| EPS Growth | -22.7% | -22.7% | -54.2% | 82.3% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
106.7%
EPS terminal req.
$4.50
Spread vs growth
-129.4%
5Y implied EPS CAGR
60.6%
EPS terminal req.
$5.45
Spread vs growth
-83.3%
10Y implied EPS CAGR
32.9%
EPS terminal req.
$8.77
Spread vs growth
-55.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.2%
Start / end P/E
58.8x → 99.5x
EPS bridge
0.66 → 0.51
Residual
-15.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.